PT  - JOURNAL ARTICLE
AU  - Sabrina Adamo
AU  - Joel Ramirez
AU  - Melissa F. Holmes
AU  - Fuqiang Gao
AU  - Ljubica Zotovic
AU  - Mario Masellis
AU  - Sandra E. Black
TI  - Ventricular expansion, white matter hyperintensities, and global cognition in Alzheimer’s disease and normal aging
AID  - 10.1101/2020.11.30.20240879
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.30.20240879
4099  - http://medrxiv.org/content/early/2020/11/30/2020.11.30.20240879.short
4100  - http://medrxiv.org/content/early/2020/11/30/2020.11.30.20240879.full
AB  - Background The progression of Alzheimer’s Disease (AD) may be tracked by measuring the growth of the ventricular cerebrospinal fluid (vCSF) over time. AD is commonly comorbid with markers of cerebral small vessel disease (SVD), viewed on MRI as white matter hyperintensities (WMH). Larger WMH volumes are correlated with poorer cognitive test scores. Additionally, periventricular WMHs have a proposed relationship to the vCSF.Purpose This study will examine ventricular expansion and its associations between periventricular/deep WMH and cognition in AD and normal aging.Methods Baseline and 1-year follow-up data were collected from AD (n=117) and cognitively normal control (NCs; n=49) participants taking part in the Sunnybrook Dementia Study. MRI (1.5T) and scores from both the Mini-Mental State Examination (MMSE) and the Dementia Rating Scale (DRS) were assessed at each time point. Volumetric data was generated using a semi-automated pipeline and each individual’s vCSF and WMHs were transformed to an intermediate space to determine volumetric growth. Regressions were used to determine relationships between vCSF growth measures, SVD burden, and cognition, accounting for demographics and individual interscan intervals.Results The AD group displayed 14.6% annual ventricular growth as opposed to NC who had only 11.8% annual growth. AD showed significant growth in vCSF (p < 0.001), a trend toward greater pWMH growth (p = 0.06) and no difference in dWMH growth volumes compared to NC. vCSF growth was positively associated with pWMH (β = 0.32, p < 0.001) but not dWMH growth in AD while in NC it was associated with both pWMH (β = 0.48, p < 0.001) and dWMH growth (β = 0.35, p = 0.02). In AD, vCSF growth was associated with the both the MMSE (β = -0.30, p < 0.001) and the DRS (β = -0.31, p < 0.001) in separate models.Conclusions The findings from this study suggest that in just under 1.5 years, the significantly rapid ventricular expansion observed in AD may be closely related to periventricular small vessel disease. As vCSF growth rates are an important biomarker of AD neurodegeneration that corresponds with cognitive decline, future research should further explore atrophy associated with periventricular vasculopathy.Trial Registration ClinicalTrials.gov, NCT01800214. Registered on 27 February 2013.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01800214Funding StatementJR, MFH, SA and FG gratefully acknowledge financial and salary support from the Canadian Institutes of Health Research (#125740 & #13129), Heart & Stroke Foundation Canadian Partnership for Stroke Recovery, Hurvitz Brain Sciences Research program at Sunnybrook Research Institute, and the Linda C. Campbell Foundation. JR additionally received partial funding from the Ontario Brain Institute's Ontario Neurodegenerative Disease Research Initiative (Note: the opinions, results, and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred). Lastly, MM and SEB would like to graciously thank the Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Department of Medicine, and the University of Toronto for financial and salary support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sunnybrook Research Ethics BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly available due to consent-related issues conducting research embedded in care, however, data can be made available from the corresponding author upon request.ADAlzheimer’s Disease;ADNIAlzheimer’s Disease Neuroimaging Initiative;ANOVAanalysis of variance;BPFbrain parenchymal fraction;(v/s) CSFventricular/sulcal cerebrospinal fluid);DRSDementia Rating Scale;ISIinterscan interval;MMSEMini-Mental State Examination;MRImagnetic resonance imaging;NAGMnormal appearing grey matter;NAWMnormal appearing white matter;NCcognitively normal control;NIA-AANational-Institute on Aging-Alzheimer’s Association;SDSSunnybrook Dementia Study;ST-TIVsupratentorial-total intracranial volume;SVDcerebral small vessel disease;(d/p) WMHdeep/periventricular white matter hyperintensity;YOEyears of education